Takeshi Miyamoto

Director, CMC


Mr. Miyamoto has more than 25 years of experience in CMC-RA area of pharmaceutical development across a wide range of products including controlled release drugs and genetic recombinants. He has excellent expertise in reviewing and drafting CTD documents in both English and Japanese in order to fulfill Japanese regulatory requirements.

Prior to joining IDEC, he worked for Japanese subsidiaries of global pharmaceutical companies including BMS, Novo, Janssen, US-Merck, and Ferring as a CMC-RA expert or the head of CMC-RA section.

Ready for regulatory clarity? Contact us.